ClinicalTrials.gg
CompletedNCT00065507Updated Jun 24, 2013Results posted

Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation

A Phase 3 interventional study of Entecavir (ETV) and Adefovir (ADV) in Hepatitis B, sponsored by Bristol-Myers Squibb. Completed at 61 sites in 17 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-06-24.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.

Enrollment
9th of 36
195 · median 106
Started
2003
the only one that year
Phase 3
4 of 37
none open now
Registered
2nd of 37
by date
Lead sponsor
6 of 37
Bristol-Myers Squibb

Among the 37 studies testing entecavir in Hepatitis B, this one is the 9th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2003, is one of 4 in phase 3, and was the 2nd registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing entecavir in Hepatitis B, or all of them as a file.
02

Study summary

This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation. The patients are treated for 96 weeks after the last subject is randomized.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • hepatic decompensation
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (CP) score >= 7
  • virus (HBV) viremia

Exclusion criteria

Exclusion

  • (ALT) > 15 x (ULN)
  • (HIV)/ virus (HCV)/hepatitis D virus (HDV) coinfection
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    A1

    Drug: Entecavir (ETV)

  • Active comparator
    A2

    Drug: Adefovir (ADV)

Interventions

  • Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized

    Also known as: Baraclude, BMS-200475

  • Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24

    Mean reduction in serum HBV DNA determined by PCR assay (log10 copies/mL) at Week 24 adjusted for baseline HBV DNA and lamivudine resistance (LVDr) status, based on linear regression analysis.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in HBV DNA by PCR at Week 48

    Mean change from baseline in HBV DNA by PCR at Week 48, adjusted for baseline HBV DNA and LVDr Status.

    Time frame: Baseline, Week 48

  2. Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24

    Time frame: Week 24

  3. Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48

    Time frame: Week 48

  4. Number of Participants Achieving Alanine Transaminase (ALT) Normalization (≤1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48

    Number of participants in each group who achieved ALT normalization (≤1.0 x upper limit of normal \[ULN\]) among those with baseline ALT \>1.0 x ULN at Weeks 24 and 48

    Time frame: Week 24, Week 48

  5. Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48

  6. >=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48

    Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  7. Number of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48

    Number of participants in each group with improvement or no worsening in Child-Pugh score from baseline to Week 48 as measured by improvement or no worsening in Child-Pugh score. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48

  8. Change From Baseline in Child-Pugh Score Through Week 48

    Mean change from baseline in Child-Pugh score through week 48. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  9. Number of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48

    Number of Participants in each group with improvement in Child-Pugh score from baseline to Week 48 as measured by improvement in Child-Pugh class. Improvement in Child-Pugh Class is defined as change from B to A or C to A. Evaluable subjects are subjects with Child-Pugh Class B or C at Baseline. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). Child-Pugh class A to C employs the added score from above: 5-6=Class A; 7-9=Class B; 10-15=Class C.

    Time frame: Week 24, Week 48

  10. Mean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48

    Adjusted mean change from baseline in MELD score through Week 48 (adjusted for baseline value). The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; \<10=4% mortality.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  11. Improvement or No Worsening in MELD Score Through Week 48

    Participants with improvement or no worsening (any decrease or no change from baseline in score) in MELD score through Week 48. The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; \<10=4% mortality.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48

  12. Mean Changes From Baseline in Quality of Life as Measured by the Short Form 36 (SF-36)

    Scoring for the SF-36 will be done using the algorithm developed by the Research ANd Development(RAND) Corporation (a scale of 0-100). Higher scores represent better quality of life. Coding for items with 2-category responses=0 and 100; 3-category=0/50/100; 5-category=0/25/50/75/100; 6-category=0/20/40/60/80/100. Scores of items in the same scale are combined to create the 8 scale scores (physical functioning, role-physical, bodily-pain, general health, vitality, social functioning, role-emotional, mental health). Physical and mental health composite scores will be computed for the group.

    Time frame: Baseline, Week 24, Week 48

  13. Mean Changes From Baseline in Quality of Life, as Measured by EuroQol-5D (EQ-5D) at Weeks 24 and 48

    The EQ-5D has 5 attributes (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression), each with 3 levels (no problem, some problems, and major problems). This algorithm gives valuation (weights) to each of the 15 responses on the form. Each valuation is a negative number, subtracted from the maximum score of 1 (perfect well being). The overall health index score ranges from 0 (dead) to 1 (perfect health) value scale, and the visual analog scale ranges from 0 to 100. Item weights will be obtained from the EuroQol group.

    Time frame: Baseline, Week 24, Week 48

  14. Change From Baseline in Albumin Through Week 48

    Mean albumin levels, and mean change from baseline in albumin, a measure of synthetic liver function. Normal range for albumin = 3.5 - 5.3 g/dL.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  15. Mean Change From Baseline in Prothrombin Time Through Week 48

    Mean prothrombin time, and mean change from baseline in prothrombin time, a measure of synthetic liver function. Prothrombin time is the time it takes (in seconds) for a sample of blood to clot. Normal range for prothrombin time (PT) = 10-13 seconds.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  16. Mean Change From Baseline in Total Bilirubin Through Week 48

    Mean total bilirubin levels, and mean change from baseline in total bilirubin, a measure of liver secretory function.Normal range for total bilirubin = 0.2 - 1.2 mg/dL.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  17. Change From Baseline in Platelet Count Through Week 48

    Mean baseline platelet count and mean change from baseline in platelet count at specific timepoints. Platelets are the smallest particles found in the blood, which play a major role in forming blood clots. Normal range for platelets = 140 - 450 X 10\*9 c/L.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  18. Participants Achieving Albumin Normalization Through Week 48

    Number of participants who achieved normalization of albumin (\>= 1 x lower limit of normal \[LLN\]), a measure of liver function, at specific timepoints.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  19. Participants Achieving Prothrombin Time Normalization Through Week 48

    Number of participants who achieved normalization of prothrombin time (\<= 1 x ULN), a measure of liver function, at specific timepoints.

    Time frame: Baseline, Week4, Week 8, Week 12, Week 24, Week 36, Week 48

  20. Participants Achieving Total Bilirubin Normalization Through Week 48

    Number of participants who achieved normalization of total bilirubin (\<= 1 x ULN), a measure of liver function, at specific timepoints.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  21. Participants Achieving Platelet Count Normalization Through Week 48

    Number of participants who achieved normalization of platelet count (\>= 1 x lower limit of normal \[LLN\]), a measure of liver function, at specific timepoints.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

  22. Number of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48

    HCC-free survival was analyzed using life tables. Measured values show the number of HCC events among treated participants at given time points.

    Time frame: Week 48

  23. Cumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL

    AE=any new untoward medical occurrence/worsening of a pre-existing medical condition regardless of causal relationship. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires/prolongs inpatient hospitalization; results in persistent/significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death. Confirmed increase in serum creatinine=values ≥0.5 mg/dL compared with baseline on 2 sequential measures.

    Time frame: on-treatment events obtained after the start of therapy and no more than 5 days after the last dose of study therapy.

  24. Number of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data

    Grade 3/4 laboratory abnormalities (hematology, electrolyte, lipase, liver function, metabolic, renal function, urinalysis). The Week 48 data set was used to evaluate the Week-48 on-treatment safety. The cumulative data set was used to evaluate the safety while on treatment. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death.

    Time frame: Week 48=all on-treatment laboratory measurements up to Week 48. Cumulative data = on-treatment laboratory measurements obtained after the start of therapy and no more than 5 days after the last dose of study therapy.

  25. Number of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment

    ALT flare=ALT \> 2 x baseline and \> 10 x upper limit of normal (ULN) by clinical laboratory evaluation. Table includes number of participants with selected clinical events and/or laboratory abnormalities during ALT flares. Selected clinical events during ALT flares=ascites, hepatic encephalopathy, jaundice, bacterial peritonitis. Selected Laboratory abnormalities during ALT flares=international normalized ratio \> 1.5 or prothrombin time \>= 1.2 x ULN and total bilirubin \>2.5 mg/dL and \> 1 mg/dL increase from baseline.

    Time frame: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date.

  26. Number of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period

    Data includes type of malignant neoplasm.

    Time frame: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up.

  27. Number of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up

    Time frame: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up.

07

Results

Posted Jul 2, 2010

Participant flow

Participant flow — Overall Study
MilestoneEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Started10091
Treated (as-randomized population)10091
Treated (as-treated population)10289
Treated, wk 48 (as-treated population)10289
Treated, 24-week follow-up population2528
Completed7162
Not completed2929
Withdrew: Death1617
Withdrew: Adverse event43
Withdrew: Lack of efficacy06
Withdrew: Poor/non-compliance32
Withdrew: Lost to follow-up30
Withdrew: Subject withdrew consent21
Withdrew: Subject no longer meets study criteria10

Outcome measures

PrimaryChange From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24

Mean reduction in serum HBV DNA determined by PCR assay (log10 copies/mL) at Week 24 adjusted for baseline HBV DNA and lamivudine resistance (LVDr) status, based on linear regression analysis.

Time frame:
Baseline, Week 24
Reported as:
Mean · log10 copies/mL
Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24
log10 copies/mLEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24-4.48 ± 0.200-3.40 ± 0.255
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Regression, Linear · p = <0.0001 · Mean difference (final values): -1.74 · 95% CI -2.30 to -1.18Linear regression model adjusted for baseline HBV DNA and LVDr status.
SecondaryChange From Baseline in HBV DNA by PCR at Week 48

Mean change from baseline in HBV DNA by PCR at Week 48, adjusted for baseline HBV DNA and LVDr Status.

Time frame:
Baseline, Week 48
Reported as:
Mean · log10 copies/mL
Change From Baseline in HBV DNA by PCR at Week 48
log10 copies/mLEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Change From Baseline in HBV DNA by PCR at Week 48-4.66 ± 0.204-3.90 ± 0.353
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Regression, Linear · p = <0.0001 · Mean difference (final values): -1.4 · 95% CI -1.85 to -0.96adjusted for baseline HBV DNA and LVDr Status
SecondaryNumber of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24
Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 244915
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Mean percent difference: 32.7 · 95% CI 20.2 to 45.2
SecondaryNumber of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48
Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48
ParticipantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 485718
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Mean percent treatment difference: 38 · 95% CI 24.8 to 50.3
SecondaryNumber of Participants Achieving Alanine Transaminase (ALT) Normalization (≤1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48

Number of participants in each group who achieved ALT normalization (≤1.0 x upper limit of normal \[ULN\]) among those with baseline ALT \>1.0 x ULN at Weeks 24 and 48

Time frame:
Week 24, Week 48
Reported as:
Number · Participants
Number of Participants Achieving Alanine Transaminase (ALT) Normalization (≤1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48
ParticipantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Week 244628
Week 484933
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Cochran-Mantel-Haenszel · p = 0.0193 · Percent treatment difference: 19.2 · 95% CI 3.7 to 34.6
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Cochran-Mantel-Haenszel · p = 0.0425 · Percent treatment difference: 16.4 · 95% CI 0.9 to 32.0
SecondaryNumber of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48
Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 48
Reported as:
Number · Participants
Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48
ParticipantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline31
Week 4236
Week 83411
Week 123716
Week 244924
Week 485734
Secondary>=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48

Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Number · Participants
>=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48
ParticipantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline00
Week 41411
Week 82310
Week 122211
Week 243222
Week 363519
Week 483525
SecondaryNumber of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48

Number of participants in each group with improvement or no worsening in Child-Pugh score from baseline to Week 48 as measured by improvement or no worsening in Child-Pugh score. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 48
Reported as:
Number · Participants
Number of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48
ParticipantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline00
Week 46667
Week 86762
Week 126862
Week 246665
Week 486161
SecondaryChange From Baseline in Child-Pugh Score Through Week 48

Mean change from baseline in Child-Pugh score through week 48. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in Child-Pugh Score Through Week 48
units on a scaleEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline Value (n=100, n=91)8.8 ± 0.208.4 ± 0.19
Change at Week 4 (n=90; n=85)-0.4 ± 0.14-0.3 ± 0.14
Change at Week 8 (n=90; n=79)-0.4 ± 0.18-0.3 ± 0.17
Change at Week 12 (n=87; n=80)-0.6 ± 0.18-0.3 ± 0.15
Change at Week 24 (n=80; n=77)-1.2 ± 0.20-0.7 ± 0.18
Change at Week 36 (n=75; n=70)-1.6 ± 0.25-0.9 ± 0.18
Change at Week 48 (n=72; n=64)-1.7 ± 0.26-1.3 ± 0.19
SecondaryNumber of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48

Number of Participants in each group with improvement in Child-Pugh score from baseline to Week 48 as measured by improvement in Child-Pugh class. Improvement in Child-Pugh Class is defined as change from B to A or C to A. Evaluable subjects are subjects with Child-Pugh Class B or C at Baseline. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). Child-Pugh class A to C employs the added score from above: 5-6=Class A; 7-9=Class B; 10-15=Class C.

Time frame:
Week 24, Week 48
Reported as:
Number · Participants
Number of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48
ParticipantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Week 242522
Week 483529
SecondaryMean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48

Adjusted mean change from baseline in MELD score through Week 48 (adjusted for baseline value). The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; \<10=4% mortality.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Mean · units on a scale
Mean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48
units on a scaleEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline Value (n=100; n=91)17.1 ± 0.5015.3 ± 0.48
Week 4 (n=97; n=87)-0.1 ± 0.380.1 ± 0.25
Week 8 (n=90; n=79)-0.8 ± 0.35-0.4 ± 0.34
Week 12 (n=88; n=80)-1.2 ± 0.41-0.9 ± 0.32
Week 24 (n=80; n=77)-2.0 ± 0.45-0.9 ± 0.46
Week 36 (n=75; n=70)-2.3 ± 0.57-1.2 ± 0.48
Week 48 (n=72; n=62)-2.6 ± 0.62-1.7 ± 0.50
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Regression, Linear · p = 0.51 · Mean difference (final values): -0.41 · 95% CI -1.63 to 0.82Model estimate incorporates prognostic factors measured at baseline. Adjusted for baseline
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Regression, Linear · p = <0.0001 · Mean difference (final values): 0.59 · 95% CI -1.08 to 1.88Model estimate incorporates prognostic factors measured at baseline. Adjusted for baseline
SecondaryImprovement or No Worsening in MELD Score Through Week 48

Participants with improvement or no worsening (any decrease or no change from baseline in score) in MELD score through Week 48. The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; \<10=4% mortality.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 48
Reported as:
Number · Participants
Improvement or No Worsening in MELD Score Through Week 48
ParticipantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline00
Week 45851
Week 86352
Week 126760
Week 246251
Week 485347
SecondaryMean Changes From Baseline in Quality of Life as Measured by the Short Form 36 (SF-36)

Scoring for the SF-36 will be done using the algorithm developed by the Research ANd Development(RAND) Corporation (a scale of 0-100). Higher scores represent better quality of life. Coding for items with 2-category responses=0 and 100; 3-category=0/50/100; 5-category=0/25/50/75/100; 6-category=0/20/40/60/80/100. Scores of items in the same scale are combined to create the 8 scale scores (physical functioning, role-physical, bodily-pain, general health, vitality, social functioning, role-emotional, mental health). Physical and mental health composite scores will be computed for the group.

Time frame:
Baseline, Week 24, Week 48

No measurements were reported for this outcome.

SecondaryMean Changes From Baseline in Quality of Life, as Measured by EuroQol-5D (EQ-5D) at Weeks 24 and 48

The EQ-5D has 5 attributes (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression), each with 3 levels (no problem, some problems, and major problems). This algorithm gives valuation (weights) to each of the 15 responses on the form. Each valuation is a negative number, subtracted from the maximum score of 1 (perfect well being). The overall health index score ranges from 0 (dead) to 1 (perfect health) value scale, and the visual analog scale ranges from 0 to 100. Item weights will be obtained from the EuroQol group.

Time frame:
Baseline, Week 24, Week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline in Albumin Through Week 48

Mean albumin levels, and mean change from baseline in albumin, a measure of synthetic liver function. Normal range for albumin = 3.5 - 5.3 g/dL.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Mean · g/dL
Change From Baseline in Albumin Through Week 48
g/dLEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline Value (n=100; n=91)3.00 ± 0.553.10 ± 0.067
Change at Week 4 (n=98; n=88)-0.04 ± 0.032-0.01 ± 0.033
Change at Week 8 (n=92; n=82)0.01 ± 0.034-0.03 ± 0.037
Change at Week 12 (n=88; n=80)0.05 ± 0.0390.03 ± 0.037
Change at Week 24 (n=81; n=77)0.26 ± 0.0560.20 ± 0.048
Change at Week 36 (n=76; n=70)0.36 ± 0.0620.25 ± 0.052
Change at Week 48 (n=72; n=63)0.49 ± 0.0610.34 ± 0.057
SecondaryMean Change From Baseline in Prothrombin Time Through Week 48

Mean prothrombin time, and mean change from baseline in prothrombin time, a measure of synthetic liver function. Prothrombin time is the time it takes (in seconds) for a sample of blood to clot. Normal range for prothrombin time (PT) = 10-13 seconds.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Mean · seconds
Mean Change From Baseline in Prothrombin Time Through Week 48
secondsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline Value (n=100; n=91)16.28 ± 0.23415.35 ± 0.196
Change at Week 4 (n=98; n=87)-0.08 ± 0.1560.03 ± 0.114
Change at Week 8 (n=91; n=79)-0.10 ± 0.1580.06 ± 0.161
Change at Week 12 (n=88; n=80)-0.29 ± 0.153-0.05 ± 0.162
Change at Week 24 (n=80; n=77)-0.75 ± 0.216-0.18 ± 0.205
Change at Week 48 (n=72; n=63)-0.99 ± 0.288-0.52 ± 0.197
SecondaryMean Change From Baseline in Total Bilirubin Through Week 48

Mean total bilirubin levels, and mean change from baseline in total bilirubin, a measure of liver secretory function.Normal range for total bilirubin = 0.2 - 1.2 mg/dL.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Mean · mg/dL
Mean Change From Baseline in Total Bilirubin Through Week 48
mg/dLEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline Value (n=100; n=91)2.80 ± 0.2072.50 ± 0.214
Change at Week 4 (n=98; n=88)-0.06 ± 0.1540.21 ± 0.172
Change at Week 8 (n=92; n=82)0.11 ± 0.376-0.17 ± 0.094
Change at Week 12 (n=88;l n=80)-0.20 ± 0.193-0.28 ± 0.109
Change at Week 24 (n=81; n=77)-0.41 ± 0.154-0.14 ± 0.227
Change at Week 36 (n=76; n=70)-0.36 ± 0.329-0.09 ± 0.298
Change at Week 48 (n=72; n=63)-0.61 ± 0.233-0.10 ± 0.450
SecondaryChange From Baseline in Platelet Count Through Week 48

Mean baseline platelet count and mean change from baseline in platelet count at specific timepoints. Platelets are the smallest particles found in the blood, which play a major role in forming blood clots. Normal range for platelets = 140 - 450 X 10\*9 c/L.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Mean · 10*9 c/L
Change From Baseline in Platelet Count Through Week 48
10*9 c/LEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline Value (n=97; n=91)87.32 ± 4.77193.31 ± 4.947
Change at Week 4 (n=90; n=85)-0.93 ± 2.064-2.14 ± 2.553
Change at Week 8 (n=82; n=76)3.55 ± 3.0633.88 ± 2.923
Change at Week 12 (n=85; n=79)4.36 ± 2.837-0.81 ± 2.814
Change at Week 24 (n=77; n=76)2.47 ± 2.556-2.89 ± 3.205
Change at Week 36 (n=72; n=69)6.56 ± 3.5341.32 ± 3.188
Change at Week 48 (n=68; n=63)10.19 ± 4.9563.05 ± 3.570
SecondaryParticipants Achieving Albumin Normalization Through Week 48

Number of participants who achieved normalization of albumin (\>= 1 x lower limit of normal \[LLN\]), a measure of liver function, at specific timepoints.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Number · participants
Participants Achieving Albumin Normalization Through Week 48
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline00
Week 427
Week 896
Week 12611
Week 242014
Week 362914
Week 483220
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Difference estimate: 10.4 · 95% CI -4.5 to 25.2
SecondaryParticipants Achieving Prothrombin Time Normalization Through Week 48

Number of participants who achieved normalization of prothrombin time (\<= 1 x ULN), a measure of liver function, at specific timepoints.

Time frame:
Baseline, Week4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Number · participants
Participants Achieving Prothrombin Time Normalization Through Week 48
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline00
Week 434
Week 854
Week 1243
Week 2496
Week 36105
Week 4887
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Difference estimate: -0.4 · 95% CI -8.7 to 8.0
SecondaryParticipants Achieving Total Bilirubin Normalization Through Week 48

Number of participants who achieved normalization of total bilirubin (\<= 1 x ULN), a measure of liver function, at specific timepoints.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Number · participants
Participants Achieving Total Bilirubin Normalization Through Week 48
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline00
Week 449
Week 8109
Week 1289
Week 241210
Week 36917
Week 481518
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Difference estimate: -7.2 · 95% CI -21.3 to 6.9
SecondaryParticipants Achieving Platelet Count Normalization Through Week 48

Number of participants who achieved normalization of platelet count (\>= 1 x lower limit of normal \[LLN\]), a measure of liver function, at specific timepoints.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Reported as:
Number · participants
Participants Achieving Platelet Count Normalization Through Week 48
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Baseline00
Week 434
Week 835
Week 1273
Week 2422
Week 3652
Week 4861
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Difference estimate: 5.7 · 95% CI -0.3 to 11.7
SecondaryNumber of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48

HCC-free survival was analyzed using life tables. Measured values show the number of HCC events among treated participants at given time points.

Time frame:
Week 48
Reported as:
Number · HCC events
Number of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48
HCC eventsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Weeks 0-4 (n=102; n=89)23
Weeks 4-8 (n=99; n=86)55
Weeks 8-12 (n=96; n=83)106
Weeks 12-16 (n=90; n=80)119
Weeks 16-20 (n=87; n=77)1111
Weeks 20-24 (n=86; n=75)1614
Weeks 24-28 (n=81; n=71)1715
Weeks 28-32 (n=78; n=70)1717
Weeks 32-36 (n=77; n=66)1718
Weeks 36-40 (n=77; n=64)1920
Weeks 40-44 (n=73; n=62)2120
Weeks 44-48 (n=71; n=62)2422
Statistical analysis
  • Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg · Regression, Cox · p = 0.20 · Hazard ratio (hr): 0.74 · 95% CI 0.46 to 1.18Cox proportional hazard model, adjusted for age \<=45 versus age \>45 years, gender, and race (white versus non-white).
SecondaryCumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL

AE=any new untoward medical occurrence/worsening of a pre-existing medical condition regardless of causal relationship. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires/prolongs inpatient hospitalization; results in persistent/significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death. Confirmed increase in serum creatinine=values ≥0.5 mg/dL compared with baseline on 2 sequential measures.

Time frame:
on-treatment events obtained after the start of therapy and no more than 5 days after the last dose of study therapy.
Reported as:
Number · participants
Cumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Any AE9186
Grade 3/4 AEs5542
SAEs7059
Deaths2329
HCC1218
Discontinuations due to AEs75
Confirmed creatinine increase >= 0.5 mg/dL1721
SecondaryNumber of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data

Grade 3/4 laboratory abnormalities (hematology, electrolyte, lipase, liver function, metabolic, renal function, urinalysis). The Week 48 data set was used to evaluate the Week-48 on-treatment safety. The cumulative data set was used to evaluate the safety while on treatment. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death.

Time frame:
Week 48=all on-treatment laboratory measurements up to Week 48. Cumulative data = on-treatment laboratory measurements obtained after the start of therapy and no more than 5 days after the last dose of study therapy.
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data
participantsWeek 48 - Entecavir (ETV) 1.0 mgWeek 48 - Adefovir (ADV) 10 mgCumulative - Entecavir (ETV) 1.0 mgCumulative - Adefovir (ADV) 10 mg
Hemoglobin881110
International Normalized Ratio30224032
Platelet Count20212524
Prothrombin Time2072511
Bicarbonate, Low3444
Chloride, Serum, Low2222
Bicarbonate/Carbon Dioxide, Low3444
Potassium, Serum, High1010
Sodium, Serum6365
Sodium, Serum, Low6365
Lipase, Total (colorimetric assay)17182325
Alanine Aminotransferase (ALT)3154
Albumin9393
Alkaline Phosphatase (ALP)0111
Aspartate Aminotransferase (AST)7397
Bilirubin, Total19182425
G-Glutamyl Transferase (GGT)16910
Glucose, Fasting Serum, High0010
Creatinine1020
Phosphorus, inorganic0406
Blood, urine13131822
Glucose, urine11111713
Protein, urine1224
Neutrophils (relative)0101
Neutrophils + Bands (relative)2448
Neutrophils (absolute)2357
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment

ALT flare=ALT \> 2 x baseline and \> 10 x upper limit of normal (ULN) by clinical laboratory evaluation. Table includes number of participants with selected clinical events and/or laboratory abnormalities during ALT flares. Selected clinical events during ALT flares=ascites, hepatic encephalopathy, jaundice, bacterial peritonitis. Selected Laboratory abnormalities during ALT flares=international normalized ratio \> 1.5 or prothrombin time \>= 1.2 x ULN and total bilirubin \>2.5 mg/dL and \> 1 mg/dL increase from baseline.

Time frame:
On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date.
Reported as:
Number · participants
Number of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
ALT flares21
ALT flares, no clinical events/lab abnormalities10
ALT flares, with clinical events/lab abnormalities11
SecondaryNumber of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period

Data includes type of malignant neoplasm.

Time frame:
On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up.
Reported as:
Number · participants
Number of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Any Adverse Events1418
Hepatic Neoplasm, Malignant1218
Basal Cell Carcinoma10
Lymph Node Cancer, Metastatic10
Hepatic Mass10
SecondaryNumber of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up
Time frame:
On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up.
Reported as:
Number · participants
Number of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up
participantsEntecavir (ETV) 1.0 mgAdefovir (ADV) 10 mg
Liver Transplant: Yes113
Liver Transplant: No9186

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADEFOVIR—59/89 (66.3%)76/89 (85.4%)
ENTECAVIR—70/102 (68.6%)77/102 (75.5%)
Most frequent serious events
Showing 10 of 148
Most frequent serious events
EventADEFOVIRENTECAVIR
HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)15/8912/102
PROTHROMBIN TIME PROLONGEDInvestigations13/8914/102
HEPATIC ENCEPHALOPATHYNervous system disorders9/8910/102
HEPATIC FAILUREHepatobiliary disorders2/8910/102
BLOOD BILIRUBIN INCREASEDInvestigations6/898/102
LIVER TRANSPLANTSurgical and medical procedures0/897/102
PERITONITIS BACTERIALInfections and infestations6/896/102
INTERNATIONAL NORMALISED RATIO INCREASEDInvestigations5/895/102
SEPSISInfections and infestations3/895/102
ASCITESGastrointestinal disorders4/894/102
Most frequent other events
Showing 10 of 42
Most frequent other events
EventADEFOVIRENTECAVIR
OEDEMA PERIPHERALGeneral disorders21/8918/102
HEADACHENervous system disorders18/897/102
DIARRHOEAGastrointestinal disorders18/8915/102
PYREXIAGeneral disorders16/8920/102
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations14/8919/102
COUGHRespiratory, thoracic and mediastinal disorders15/8917/102
ASCITESGastrointestinal disorders14/8914/102
FATIGUEGeneral disorders13/8913/102
ABDOMINAL PAINGastrointestinal disorders12/8914/102
VOMITINGGastrointestinal disorders8/8912/102

Baseline characteristics

Age Continuous
Age Continuous(years)Entecavir (ETV) 1.0 mgAdefovir (ADV) 10 mgTotal
Mean51 ± 1253 ± 1152 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Entecavir (ETV) 1.0 mgAdefovir (ADV) 10 mgTotal
Female222749
Male7864142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Entecavir (ETV) 1.0 mgAdefovir (ADV) 10 mgTotal
Asian5549104
White352863
Other5914
Black/African American5510
Region of Enrollment
Region of Enrollment(participants)Entecavir (ETV) 1.0 mgAdefovir (ADV) 10 mgTotal
United States12921
Philippines459
Taiwan111122
Hong Kong5510
Greece8513
Thailand10919
Indonesia202
Turkey314
Russian Federation112
India151429
Canada538
Brazil131326
Poland358
Singapore358
South Africa347
France202
United Kingdom011
Child-Pugh Class
Child-Pugh Class(Participants)Entecavir (ETV) 1.0 mgAdefovir (ADV) 10 mgTotal
Class A71017
Class B6361124
Class C302050
Alanine Aminotransferase (ALT)
Alanine Aminotransferase (ALT)(U/L)Entecavir (ETV) 1.0 mgAdefovir (ADV) 10 mgTotal
Mean99.2 ± 111.23100.0 ± 81.6899.6 ± 98.01
Child-Pugh Score
Child-Pugh Score(units on a scale)Entecavir (ETV) 1.0 mgAdefovir (ADV) 10 mgTotal
Mean8.81 ± 1.988.35 ± 1.828.59 ± 1.91
HBV DNA by PCR
HBV DNA by PCR(log10 copies/mL)Entecavir (ETV) 1.0 mgAdefovir (ADV) 10 mgTotal
Mean7.53 ± 1.8298.16 ± 2.1797.83 ± 2.023

1 further baseline measures are reported on the registry.

08

Study locations

61 sites
  • Research And Education, Inc.
    San Diego, California 92115, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06520, United States
  • University Of Miami School Of Medicine
    Miami, Florida 33136, United States
  • Pediatric Gasteroenterology
    Atlanta, Georgia 30342, United States
  • Hawaii Medical Center East
    Honolulu, Hawaii 96817, United States
  • Indiana University Med Center
    Indianapolis, Indiana 46202-5121, United States
  • The Cht Liver Research Center
    Louisville, Kentucky 40292, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Henry Ford Health System Irb
    Detroit, Michigan 48202, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Columbia Presbyterian Medical Center (Cpmc)
    New York, New York 10032, United States
  • Integris Baptist Medical Center
    Oklahoma City, Oklahoma 73112, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Ut Southwestern Medical Center
    Dallas, Texas 75390-9151, United States
  • Mcguire Dvamc
    Richmond, Virginia 23249, United States
  • Local Institution
    Porto Alegre - Rs, Rio Grande Do Sul 90035-003, Brazil
  • Local Institution
    Sao Paulo - Sp, Sao Paulo 05403-900, Brazil
  • Local institution
    Sao Paulo, 01246-000, Brazil
  • Local Institution
    Sao Paulo, 01246-903, Brazil
  • Local Institution
    Calgary, Alberta T2N 4N1, Canada
  • Local Institution
    Vancouver, British Columbia V5Z 1H2, Canada
  • Local Institution
    Clichy Cedex, 92118, France
  • Local Institution
    Strasbourg, 67100, France
  • Local institution
    Athens, 11522, Greece
  • Local Institution
    Athens, 11527, Greece
  • Local Institution
    Athens, 15127, Greece
  • Local Instituition
    Thessaloniki, 54006, Greece
  • Local Institution
    Thessaloniki, 570 10, Greece
  • Local Institution
    Tai Po, Hong Kong
  • Local Institution
    Hyderabad, Andhra Pradesh 500082, India
  • Local Institution
    Kolkata, 700020, India
  • Local Institution
    Lucknow, 226014, India
  • Local Institution
    New Delhi, 110002, India
  • Local Institution
    Jakarta, 10430, Indonesia
  • Local Institution
    Cebu, 6000, Philippines
  • Local Institution
    Manila, 1008, Philippines
  • Local Institution
    Bydgoszcz, 85-030, Poland
  • Local Institution
    Chorzow, 41-500, Poland
  • Local Institution
    Krakow, 31-202, Poland
  • Local Institution
    Lodz, 91-347, Poland
  • Local Institution
    Moscow, 115446, Russian Federation
  • Local Institution
    Moscow, 117333, Russian Federation
  • Local Institution
    Smolensk, 214018, Russian Federation
  • Local Institution
    Singapore, 119228, Singapore
  • Local Institution
    Singapore, 169608, Singapore
  • Local Institution
    Singapore, 308433, Singapore
  • Local Institution
    Singapore, 529889, Singapore
  • Local Institution
    Observatory, Western Cape 7925, South Africa
  • Local Institution
    Paarl, Western Cape 7620, South Africa
  • Local Institution
    Changhua, 500, Taiwan
  • Local Institution
    Taichung, 404, Taiwan
  • Local Institution
    Taipei, 100, Taiwan
  • Local Institution
    Taoyuan, 333, Taiwan
  • Local Institution
    Tianan, 704, Taiwan
  • Local Institution
    Bangkok, 10400, Thailand
  • Local Institution
    Bangkok, 10700, Thailand
  • Local Institution
    Hatyai, 90110, Thailand
  • Local Institution
    Adana, 01330, Turkey
  • Local Institution
    Izmir, 35100, Turkey
  • Local Institution
    London, Greater London NW3 2QG, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Oct 2008 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2003
First posted
Jul 29, 2003
Start
Aug 2003
Primary completionActual
Oct 2008
CompletionActual
May 2013
Results first posted
Jul 2, 2010
Last update
Jun 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00065507
Responsible party
Sponsor
First posted
Jul 29, 2003
Start date
Aug 2003
Primary completion
Oct 2008
Completion
May 2013
Results posted
Jul 2, 2010
Last update
Jun 24, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion